These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 17710071)
1. Critical GI issues for the cardiologist: new insights and understanding. Introduction. Faxon DP; Johnson DA Rev Cardiovasc Med; 2005; 6 Suppl 4():S1-2. PubMed ID: 17710071 [No Abstract] [Full Text] [Related]
2. [The gastrointestinal risk of antiplatelet agents and nonsteroidal anti-inflammatory agents. A report of the American College of Cardiology Foundation (ACCF), the American College of Gastroenterology (ACG) and the American Heart Association (AHA)]. Recenti Prog Med; 2009 May; 100(5):277-8. PubMed ID: 19772220 [No Abstract] [Full Text] [Related]
3. Upper GI risks of NSAIDs and antiplatelet agents: key issues for the cardiologist. Johnson DA Rev Cardiovasc Med; 2005; 6 Suppl 4():S15-22. PubMed ID: 17710072 [TBL] [Abstract][Full Text] [Related]
4. Strategies to reduce the GI risks of antiplatelet therapy. Scheiman JM Rev Cardiovasc Med; 2005; 6 Suppl 4():S23-31. PubMed ID: 17710073 [TBL] [Abstract][Full Text] [Related]
5. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Chan FK; Abraham NS; Scheiman JM; Laine L; Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980 [TBL] [Abstract][Full Text] [Related]
6. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Bhatt DL; Scheiman J; Abraham NS; Antman EM; Chan FK; Furberg CD; Johnson DA; Mahaffey KW; Quigley EM; Circulation; 2008 Oct; 118(18):1894-909. PubMed ID: 18836135 [No Abstract] [Full Text] [Related]
7. Daily low-dose aspirin: beware of GI bleeding. Johns Hopkins Med Lett Health After 50; 2012 Mar; 24(1):6. PubMed ID: 22493823 [No Abstract] [Full Text] [Related]
8. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Targownik LE; Metge CJ; Leung S; Chateau DG Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634 [TBL] [Abstract][Full Text] [Related]
9. [Position paper of the Working Group of Three Polish National Consultants in internal medicine, gastroenterology and cardiology concerning the rules of gastrointestinal complications' prevention during antiplatelet treatment]. Imiela J; Opolski G; Rydzewska G; Baczewska-Mazurkiewicz D; MaĆecki R; Filipiak KJ; Kardiol Pol; 2009 May; 67(5):536-8. PubMed ID: 19521941 [No Abstract] [Full Text] [Related]
10. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal. Hinz B; Renner B; Brune K Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610 [TBL] [Abstract][Full Text] [Related]
11. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Rostom A; Moayyedi P; Hunt R; Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986 [TBL] [Abstract][Full Text] [Related]
12. [Risk and prevention of gastrointestinal complications due to low-dose aspirin and other antiplatelet agents]. Bretagne JF Rev Prat; 2008 Sep; 58(13):1434-6, 1439-40. PubMed ID: 18924327 [TBL] [Abstract][Full Text] [Related]
13. Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future. Fiorucci S Gastroenterol Clin North Am; 2009 Jun; 38(2):315-32. PubMed ID: 19446261 [TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal events related to the use of non-steroidal anti-inflammatory drugs: some clinical and economic aspects. Eliakim R; Rachmilewitz D Isr J Med Sci; 1997 Oct; 33(10):696-9. PubMed ID: 9397147 [No Abstract] [Full Text] [Related]
15. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs. Scheiman JM Gastroenterol Clin North Am; 2009 Jun; 38(2):305-14. PubMed ID: 19446260 [TBL] [Abstract][Full Text] [Related]
16. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734 [TBL] [Abstract][Full Text] [Related]
17. NSAIDs, risks, and gastroprotective strategies: current status and future. Graham DY; Chan FK Gastroenterology; 2008 Apr; 134(4):1240-6. PubMed ID: 18395101 [No Abstract] [Full Text] [Related]
19. Protecting the stomach from the "toxins" of NSAIDS and anti-platelet agents. Echelmeyer S; Kanwal F Mo Med; 2009; 106(5):343-5. PubMed ID: 19902714 [TBL] [Abstract][Full Text] [Related]
20. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Bhatt DL; Scheiman J; Abraham NS; Antman EM; Chan FK; Furberg CD; Johnson DA; Mahaffey KW; Quigley EM; Harrington RA; Bates ER; Bridges CR; Eisenberg MJ; Ferrari VA; Hlatky MA; Kaul S; Lindner JR; Moliterno DJ; Mukherjee D; Schofield RS; Rosenson RS; Stein JH; Weitz HH; Wesley DJ; J Am Coll Cardiol; 2008 Oct; 52(18):1502-17. PubMed ID: 19017521 [No Abstract] [Full Text] [Related] [Next] [New Search]